Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis.

about

Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis.

Item

http://www.wikidata.org/entity/Q49545526

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Evaluation of the dose and eff ...... e patients with myelofibrosis.

@en

Evaluation of the dose and eff ...... e patients with myelofibrosis.

@nl

type

Item

label

Evaluation of the dose and eff ...... e patients with myelofibrosis.

@en

Evaluation of the dose and eff ...... e patients with myelofibrosis.

@nl

prefLabel

Evaluation of the dose and eff ...... e patients with myelofibrosis.

@en

Evaluation of the dose and eff ...... e patients with myelofibrosis.

@nl

P1476

Evaluation of the dose and eff ...... e patients with myelofibrosis.

@en

P2093

Hikaru Okada

http://www.w3.org/2001/XMLSchema#string

Hiroshi Handa

http://www.w3.org/2001/XMLSchema#string

Katsuto Takenaka

http://www.w3.org/2001/XMLSchema#string

Kazuya Shimoda

http://www.w3.org/2001/XMLSchema#string

Kazuyuki Suzuki

http://www.w3.org/2001/XMLSchema#string

Keita Kirito

http://www.w3.org/2001/XMLSchema#string

Kenji Oritani

http://www.w3.org/2001/XMLSchema#string

Kohshi Ohishi

http://www.w3.org/2001/XMLSchema#string

Koichi Akashi

http://www.w3.org/2001/XMLSchema#string

Norio Komatsu

http://www.w3.org/2001/XMLSchema#string

P2860

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

A gain-of-function mutation of JAK2 in myeloproliferative disorders

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

P2888

s12185-017-2332-z

P304

92-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12185-017-2332-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092113561

http://www.w3.org/2001/XMLSchema#string

P698

28986762

http://www.w3.org/2001/XMLSchema#string